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Abstract
Glaucoma is a neurodegenerative disease characterized by loss of retinal ganglion cells (RGCs), the output neurons of
the retina. Multiple lines of evidence show the endothelin (EDN, also known as ET) system is important in
glaucomatous neurodegeneration. To date, the molecular mechanisms within RGCs driving EDN-induced RGC death
have not been clariﬁed. The pro-apoptotic transcription factor JUN (the canonical target of JNK signaling) and the
endoplasmic reticulum stress effector and transcription factor DNA damage inducible transcript 3 (DDIT3, also known
as CHOP) have been shown to act downstream of EDN receptors. Previous studies demonstrated that JUN and DDIT3
were important regulators of RGC death after glaucoma-relevant injures. Here, we characterized EDN insult in vivo and
investigated the role of JUN and DDIT3 in EDN-induced RGC death. To accomplish this, EDN1 ligand was intravitreally
injected into the eyes of wildtype, Six3-cre+Junﬂ/ﬂ (Jun−/−), Ddit3 null (Ddit3−/−), and Ddit3−/−Jun−/− mice. Intravitreal
EDN1 was sufﬁcient to drive RGC death in vivo. EDN1 insult caused JUN activation in RGCs, and deletion of Jun from
the neural retina attenuated RGC death after EDN insult. However, deletion of Ddit3 did not confer signiﬁcant
protection to RGCs after EDN1 insult. These results indicate that EDN caused RGC death via a JUN-dependent
mechanism. In addition, EDN signaling is known to elicit potent vasoconstriction. JUN signaling was shown to drive
neuronal death after ischemic insult. Therefore, the effects of intravitreal EDN1 on retinal vessel diameter and hypoxia
were explored. Intravitreal EDN1 caused transient retinal vasoconstriction and regions of RGC and Müller glia hypoxia.
Thus, it remains a possibility that EDN elicits a hypoxic insult to RGCs, causing apoptosis via JNK-JUN signaling. The
importance of EDN-induced vasoconstriction and hypoxia in causing RGC death after EDN insult and in models of
glaucoma requires further investigation.

Introduction
Glaucoma is a neurodegenerative condition affecting
the output neurons of the retina—the retinal ganglion
cells (RGCs). The mechanisms that cause RGC insult and
death in glaucoma remain incompletely understood.
Recently, the endothelin (EDN, also known as ET) system
has been implicated in glaucomatous neurodegeneration1–6. There are three secreted EDN peptide ligands
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bound receptors (EDNRA and EDNRB). EDN ligands are
the most potent vasoactive peptides known, and the
canonical role of EDN signaling is to mediate vasoconstriction4,7,8. Changes in blood ﬂow have been documented in human9–12 and animal models5,6 of glaucoma,
and it is hypothesized that these changes could be
important factors in the development and progression of
glaucoma. EDN ligands and receptors were found to be
upregulated in models of acute13,14 and chronic ocular
hypertension1,5,6,15–17. Importantly, molecular clustering
analysis of transcriptional changes in ocular hypertensive
mouse retinas and optic nerve heads revealed that upregulation of Edn ligands and receptors was among the ﬁrst
molecular changes in glaucoma pathology1,5,6. Levels of
EDN were also found to be elevated in the aqueous humor
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and plasma of glaucoma patients3,18–20. Antagonism or
knockout of EDN receptors lessened RGC loss in models
of acute and chronic ocular hypertension1,5. In
addition, EDN delivery was sufﬁcient to drive RGC death
in vivo2,4–6,21. Despite these ﬁndings, the cell death
pathways responsible for eliciting RGC death upon EDN
insult remain unknown. Understanding the molecular
mechanisms controlling EDN-induced RGC death in
glaucoma will provide insight into early, critical pathways
of glaucomatous neurodegeneration and can identify
potential therapeutic targets for neuroprotective glaucoma treatments.
JUN N-terminal kinase (JNK) signaling has been shown
to be important in mediating glaucoma-relevant neurodegeneration22–26. JNK signaling is a mitogen activated
protein kinase phosphorelay system where MAP3Ks
phosphorylate and activate MAP2Ks (MKK4 and MKK7),
which phosphorylate and activate MAPKs (JNK). JNK
phosphorylates and activates its canonical target JUN,
which can then act as a proapoptotic transcription factor
by promoting the transcription of pro-death genes (e.g.
Bim, Faslg, and Bbc3)24,27,28. Jun deﬁciency or loss of
function was signiﬁcantly protective to RGCs after chronic
ocular hypertension25 and axonal injury22,26. Similarly,
endoplasmic reticulum stress has been implicated in
neurodegenerative diseases, including glaucoma24,26,29.
Prolonged endoplasmic reticulum stress promotes translation of DNA-damage-inducible transcript 3 (DDIT3, also
known as CHOP), which can act as a pro-apoptotic
transcription factor. Ddit3 deﬁciency was moderately
protective to RGCs after axonal injury and ocular hypertension26,29,30. Dual deletion of Jun and Ddit3 conferred
additive, near complete, and long-term protection to
RGCs following optic nerve crush26. Given the potential
importance of EDN signaling in glaucomatous neurodegeneration, it is plausible that EDN causes RGC death via
JUN and/or DDIT3 activation. Notably, both JUN and
DDIT3 have been known to act downstream of EDN
receptors. MAPKs (including JNK) and JUN were shown
to be upregulated or activated in a variety of cell types,
including cultured RGCs, after exposure to EDN31–40.
Therefore, JUN may play a role in regulating RGC death
after EDN insult. The EDN system has also been shown to
activate the endoplasmic reticulum stress response41,42.
Therefore, it is possible that JUN and/or DDIT3 are RGCintrinsic regulators of EDN-induced RGC death, similar to
after glaucoma-relevant injuries. Here, we characterized
the time course and extent of EDN insult and critically test
the importance of JUN and DDIT3 in RGC death following EDN insult in vivo.
In addition to the apoptotic RGC-autonomous
mechanisms triggered by EDN signaling, the cell types
that respond to EDN ligands to ultimately cause RGC
death
remain unknown. EDN ligands
cause
Ofﬁcial journal of the Cell Death Differentiation Association
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vasoconstriction by binding to EDNRA expressed by vascular smooth muscle cells4,7,8,43,44. Thinner retinal vessels
and evidence of hypoxia have been demonstrated in animal models of chronic glaucoma5,6,45,46. Importantly, JUN
was found be an important regulator of ischemia-induced
neuronal death47–51. Thus, it is possible that EDN elicits a
hypoxic insult to the retina via EDNRA to ultimately cause
JUN-dependent RGC loss. To clarify how EDN ligands
may be acting to cause RGC loss, we characterized changes in retinal vessel diameter and hypoxia after EDN
insult.

Materials and methods
Mice

Wild-type (WT) C57BL/6J mice and mice carrying a
germline deletion of Ddit352 (The Jackson Laboratory,
Stock# 005530) or ﬂoxed alleles of Jun53 (Junﬂ) were utilized for all experiments. All mice used were 2–6 months
of age. Floxed alleles were recombined in the optic cup
using Six3-cre54 (The Jackson Laboratory, Stock#
019755). All alleles were backcrossed >10 times to the
C57BL/6J genetic background (>99% C57BL/6J), and all
colonies were maintained by intercrossing. Mice were fed
chow and water ad libitum and housed on a 12-h light-todark cycle. Roughly equal numbers of males and females
were used for each experimental group. Animals were
randomly assigned to experimental groups. Before
experiments were performed, it was established that animals with pre-existing abnormal eye phenotypes (e.g.
displaced pupil, cataracts) would be excluded from the
study. All experiments were conducted in adherence with
the Association for Research in Vision and Ophthalmology’s statement on the use of animals in ophthalmic and
vision research and were approved by the University of
Rochester’s University Committee on Animal Resources.
Intravitreal injections

Mice were anaesthetized with an intraperitoneal injection of 0.05 ml/10 g solution containing ketamine (20 mg/
mL) and xylazine (2 mg/ mL). Eyes were sterilized with
50% betadine solution made in 1X phosphate buffered
saline (PBS), and were thoroughly ﬂushed with 1X PBS.
The conjunctiva at the temporal quadrant was cleared
away with the bevel of a 30-gauge needle, and a small
incision was made with the 30-gauge needle through the
sclera and behind the limbus. Vitreous was allowed to
drain, and any blood was wicked away. Five μL Hamilton
syringes (Hamilton Company, 7633–01) with a blunt 33gauge needle were used to perform intravitreal injections.
The needle of the Hamilton syringe was inserted 1 mm
into the incision site at a 45° angle toward the optic nerve,
and was held in place for 30 s prior to injection. Care was
taken to avoid contacting the lens with the Hamilton
needle. Before experiments were performed, it was

Marola et al. Cell Death and Disease (2020)11:811

established that eyes with observable lens damage as a
result of intravitreal injection would be excluded from the
study. Over the course of 2 min (to prevent a sudden
increase in intraocular pressure), 2 μL of 500 μM EDN1
(Sigma, E7764), diluted in sterile 1X PBS was injected into
the vitreous. The Hamilton needle was held in place for
30 s following the injection, and the needle was removed
from the eye over the course of 30 s. Antibiotic ointment
was placed over the eye. The contralateral eye was
injected with 2 μL of vehicle (sterile 1X PBS) with identical methods to serve as a control. Note: the investigator
was masked to genotype while performing intravitreal
injections.
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Table 1 Summary of antibodies.
Concentration

Company

Primary antibody (catalog number)
Rabbit anti-cCASP3 (AF835)

1:1000

R&D Systems

Goat anti-CD31 (AF3628)

1:1000

R&D Systems

Goat anti-ChAT (AB144P)

1:200

Millipore

Mouse anti-JUN

1:250

Fisher Scientiﬁc

1:200

Hypoxyprobe

(BDB610327)
Rabbit anti-pimonidazole
(PAb2627AP)
Rabbit anti-pJUN (9261S)

1:250

Cell Signaling

Fluorescein angiography

Rabbit anti-RBPMS

1:250

GeneTex

Fluorescein angiography was performed as previously
described55. Mice were anaesthetized with an intraperitoneal injection of 0.05 mL/10 g solution containing
ketamine (20 mg/mL) and xylazine (2 mg/mL). Mice were
given an intraperitoneal injection of 0.2 μL/g ﬂuorescein
(25% Fluorescein Sodium) immediately prior to angiography. Retinal vasculature was photographed using a
Micron III mouse retinal imaging system (Phoenix
Research Labs).

(GTX118619)
1:250

PhosphoSolutions

1:200

Santa Cruz

Hypoxia detection

Hypoxia was assessed using pimonidazole HCl
(Hypoxyprobe) according to manufacturer’s instructions.
Ninety minutes prior to euthanasia, mice were given an
intraperitoneal injection of (60 mg/kg) pimonidazole HCl
diluted in sterile 1X PBS. Mice were then transcardially
perfused with 20 mL saline solution and 20 mL 4% paraformaldehyde. Eyes were harvested and incubated in 4%
paraformaldehyde for 30 min. Eyes were stored in 1X PBS
until dissection. Hypoxia was detected using an antibody
against pimonidazole (Table 1).
Immunostaining and quantiﬁcation

Eyes were harvested and ﬁxed in 4% paraformaldehyde
in 1X PBS for 90 min. For retinal sections, the anterior
segment was removed and the retina was kept in the optic
cup for processing. Retinas were incubated in 10% sucrose
(in 1X PBS) overnight, 20% sucrose overnight, and 30%
sucrose for 3 days. Eyes were embedded in tissue freezing
medium (General Data, TFM-5), frozen at −80 °C, and
cross-sectioned at 14 μm. Sections were collected on glass
microscope slides, which were stored at −20 °C. For
hypoxia detection, one section every 84 μm was collected
for immunoﬂuorescence to ensure representation from
the entire retina. Sections were blocked in 10% horse
serum, 0.1% TritonX in 1X PBS for 3 h at room temperature and then incubated in primary antibody made in
10% horse serum, 0.1% TritonX overnight at 4 °C. Sections were washed in 1X PBS and incubated in secondary
Ofﬁcial journal of the Cell Death Differentiation Association

Guinea pig anti-RBPMS
(1832-RBPMS)
Goat anti-SOX2 (sc-17320)

Secondary antibody (catalog number)
Donkey anti-rabbit

1:1000

ThermoFisher

Donkey anti-guinea pig
(706–605–148)

1:1000

Jackson
ImmunoResearch

Donkey anti-goat (A21447)

1:1000

ThermoFisher

Donkey anti-mouse

1:1000

ThermoFisher

(A31572, A-21206)

(A31570)

antibody made in 1X PBS for 2 h at room temperature.
Sections were then washed, counterstained with 4′,6diamidino-2-phenylindole (DAPI), and mounted in
Fluorogel in TRIS buffer (Electron Microscopy Sciences).
A masked observer captured images. For hypoxyprobe
immunoﬂuorescence, images were exposure-matched.
Methodology for cell quantiﬁcation in retinal sections
was adapted from Harder et al.56. All sections analyzed
were a maximum of 168 μm from the optic nerve head.
Five equidistant 20× ﬁelds (444 μm) were captured
per section; two at each periphery, two at each middle
area, and one at the center. Four sections were analyzed
per retina. The cell counter tool in ImageJ was used for cell
quantiﬁcation. For each section, cell counts were summed.
The score of each retina was the average of the 4 sections’
summed cell counts normalized to the distance measured.
For whole mount staining, retinas were dissected free
from the optic cup and blocked in 10% horse serum, 0.4%
TritonX in 1X PBS overnight at 4 °C. Retinas were incubated at 4 °C for 72 h in primary antibody diluted in 10%
horse serum, 0.4% TritonX in 1X PBS. Retinas were then
washed and incubated overnight at 4 °C in secondary
antibody diluted in 1X PBS. Retinas were washed and
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Fig. 1 EDN1 caused caspase 3 activation in RGCs and RGC loss. a Caspase 3 activation in RBPMS+ RGCs after intravitreal PBS or EDN1 injection.
Caspase 3 was activated (cleaved, cCASP3, red) in RBPMS+ RGCs (green) post-EDN1 injection, which peaked after 5 days. Caspase 3 was rarely
activated in RGCs at any timepoint post-PBS injection (cCASP3+ RBPMS+ cells/mm2 ± SEM 3, 5, 10, 14 days post injection; PBS: 0.8 ± 0.2, 0.8 ± 0.2,
1.0 ± 0.3, 0.1 ± 0.1; EDN1: 3.2 ± 1.3, 31.0 ± 11.5, 5.4 ± 2.1, 5.4 ± 2.1, 1.6 ± 0.7; n ≥ 5 per condition per timepoint, *P < 0.001 compared to respective PBS,
two-way ANOVA, Holm-Sidak’s post hoc). Note: bottom row images depict RBPMS immunoﬂuorescence (left image, green) and RBPMS/cCASP3
merged immunoﬂuorescence (right image, green and red respectively) from the boxed area of the above image. Arrowheads indicate an RBPMS+
cCASP3+ cell. b EDN1-injured retinas had signiﬁcantly fewer RBPMS+ RGCs (green) compared to PBS controls 28 days post injection (%RBPMS+ cell
survival ± SEM; PBS: 100.0 ± 2.6; EDN1: 73.9 ± 3.3; n ≥ 7 per condition, *P < 0.001, unpaired two-tailed t test). Note: in some EDN1-injured retinas,
caspase activation and RGC death were localized to portions of retina and were not necessarily diffuse throughout the entire retina. Images represent
the average cell count for each condition. Error bars, SEM. Scale bars, 50 μm.

mounted ganglion cell layer-up in Flourogel in TRIS
buffer (Electron Microscopy Sciences). Note: for triple
immunoﬂuorescence, primary antibodies from three different host species were utilized, and secondary antibodies
conjugated with ﬂourophores with 3 different excitation/
emission frequencies were utilized.
As previously described22–26, RBPMS+, SOX2+, and
pJUN+ cells were quantiﬁed using eight 40× ﬁelds per
retina, and cCASP3+RBPMS+ cells were quantiﬁed using
eight 20× ﬁelds per retina. Images were equally spaced
220 μm from the peripheral edge of the retina. The cellcounter tool in ImageJ was used for quantiﬁcation. A
masked observer captured and quantiﬁed images.
To assess changes in artery and vein diameter after
EDN1 insult ex vivo, mice were trancardially perfused with
20 mL PBS and 20 mL 4% PFA 5 min after EDN1 injection.
Retinas were processed for whole mount immunostaining
as described above. Retinal artery and vein diameters were
measured using the line segment measurement tool in
ImageJ. Six measurements per CD31+ artery and vein
were taken 240 μm, 305 μm, 370 μm, 435 μm, 500 μm, and
565 μm from the optic disc. Distance from the optic disc
was chosen in order to include measurments before the
approximate location of the ﬁrst arterial bifurcations.
Arteries and veins were identiﬁed by their distinct
branching morphologies57.
Ofﬁcial journal of the Cell Death Differentiation Association

Controlled optic nerve crush

Controlled optic nerve crush (CONC) was performed as
previously described27,58. Mice were anesthetized with an
intraperitoneal injection of 0.05 ml/10 g solution containing ketamine (20 mg/mL) and xylazine (2 mg/mL).
Meloxicam (2 mg/kg) was administered subcutaneously
prior to surgery. The optic nerve was exposed and crushed immediately behind the eye with self-closing forceps
for 5 s. Antibiotic ointment was applied to the eyes after
the procedure.
Statistical analysis

Data were analyzed using GraphPad Prism8 software.
Power calculations were performed before experiments
were conducted to determine appropriate sample size. Data
from experiments designed to test differences between two
groups (e.g. %RGC survival, %pJUN+RBPMS+ cells, vessel
diameters, ChAT+cells/mm, SOX2+ cells/mm2, and
SOX2+ Müller glia/mm after PBS and EDN1 in WT mice;
Figs. 1b, 2c, 4d, and 5) were subjected to an F test to
compare variance and a Shapiro–Wilk test to test normality to ensure appropriate statistical tests were utilized.
%RGC survival (Fig. 1b), venous diameter (Fig. 4d), ChAT
+ cells/mm (Fig. 5b–d), SOX2+ cells/mm2 (Fig. 5e), and
SOX2+ Müller glia/mm (Fig. 5f) were analyzed using
unpaired two-tailed t tests. %pJUN+ RGCs (Fig. 2c) and
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Fig. 2 EDN1 caused JUN activation in RGCs. a Retinal ﬂat mounts
depicting JUN activation in RBPMS+ RGCs 24 h after PBS and EDN1
injection. b Quantiﬁcation of RBPMS+ and RBPMS- pJUN+ cells 24 h
after PBS and EDN1 injection. JUN was accumulated and activated
(phosphorylated, pJUN, red) in 1203.8 ± 9.4 RBPMS+ cells per mm2
after EDN1 injection. A small portion of pJUN+ cells (113.0 ± 9.4 cells
per mm2) were RBPMS−. n = 4 per condition, *P < 0.001, two-way
ANOVA, Holm-Sidak’s post hoc. c Percentage of pJUN+ RBPMS+ cells
after PBS and EDN1 injection. JUN was accumulated and activated
(phosphorylated, pJUN, red) in a portion of RBPMS+ (green) RGCs 24 h
post-EDN1, and was rarely activated in RBPMS+ RGCs post-PBS
(%pJUN+ RBPMS+ cells; PBS: 0.1 ± 0.1; EDN1: 30.2 ± 7.2; n = 4 per
condition, *P = 0.001, Welch’s t test). Note: in some EDN1-injured
retinas, JUN activation in RGCs was localized to portions of retina and
was not necessarily diffuse throughout the entire retina. Images
represent the average cell count for each condition. d Retinal ﬂat
mounts depicting caspase 3 activation and JUN accumulation in
RBPMS+ RGCs 5 days post- PBS and EDN1 injection. Arrows indicate
cCASP3+ JUN+ cells, arrowheads indicate cCASP3+ JUN- cells.
Merged images (far right) depict cCASP3+ (blue), JUN+ (red), and
RBPMS+ (green) cells. e Quantiﬁcation of cCASP3+ RBPMS+ cells that
were JUN+ and JUN- after PBS and EDN1 injection. After PBS, 0.9 ±
0.1 cells/mm2 were RBPMS+ cCASP3+ JUN+, and 0.1 ± 0.1 cells/mm2
were RBPMS+ cCASP3+ JUN-. After EDN1, 15.7 ± 2.8 cells per mm2
were RBPMS+ cCASP3+ JUN+, and 7.4 ± 2.7 cells per mm2 were
RBPMS+ cCASP3+ JUN−. (n = 6 per condition, *P < 0.05, two-way
ANOVA with Holm-Sidak’s post hoc test). f Comparison of the
percentage of cCASP3+ RBPMS+ cells that were JUN+ and JUN−
between EDN1 injured retinas (n = 6) and controlled optic nerve
crush-injured retinas (CONC; n = 4) 5 days post injury. Of all cCASP3+
RBPMS+ cells, 68.8 ± 8.7% were JUN+ after EDN1 insult, and 43.8 ±
9.6% were JUN+ after controlled optic nerve crush. (*P < 0.05, twoway ANOVA with Holm-Sidak’s post hoc). Scale bars, 50 μm.

arterial diameter (Fig. 4d) were analyzed using Welch’s t
test. Data from experiments designed to test differences
among more than two groups across one condition (e.g.
caspase 3 activation among WT, Ddit3−/−, and Jun−/−
retinas after EDN1, Fig. 3a) were subjected to a BrownForsythe test to compare variance and a Shapiro–Wilk test
to test normality to ensure an appropriate statistical test
was utilized. Data were analyzed using a Kruskal–Wallis
test with Dunn’s post hoc test. Data from experiments
designed to detect differences among multiple groups and
across multiple conditions (e.g. caspase 3 activation after
PBS and EDN1 at multiple timepoints, RBPMS+ and
RBPMS- pJUN+ cells after PBS and EDN1, pJUN+ and
pJUN- cCASP3+ RBPMS+ cells after PBS and EDN1, %
pJUN+ and %pJUN- cCASP3+ RBPMS+ cells after EDN1
and CONC, and %RGC survival across multiple genotype
groups after PBS and EDN1; Figs. 1a, 2b, e, f, and 3b) were
analyzed using a two-way ANOVA followed by HolmSidak’s post hoc test. For these statistical tests, every
Ofﬁcial journal of the Cell Death Differentiation Association

possible comparison was made when relevant, and multiplicity adjusted P values are reported. In all cases, data met
the assumptions of the statistical test used. P values < 0.05
were considered statistically signiﬁcant. Throughout the
manuscript, results are reported as mean ± standard error
of the mean (SEM).

Results
EDN1 caused caspase 3 activation in RGCs and RGC loss

Experiments using in vivo approaches have demonstrated that EDN exposure causes RGC death4,6,21. However, the mechanisms responsible for eliciting apoptosis
upon EDN insult remain unknown. To understand the
mechanisms of glaucoma-relevant EDN-induced RGC
death, the time course and extent of EDN injury were
characterized in vivo. To accomplish this, wild-type (WT)
C57BL/6J mice were intravitreally injected with 2 μL of
500 μM EDN1 diluted in 1X PBS (1 nmol EDN1). 1X PBS
was intravitreally injected into the contralateral eye to serve
as an internal vehicle control. Note, this injection paradigm
was used for all experiments. In models of chronic ocular
hypertension, RGCs die via apoptosis58, a process mediated
by cleavage of caspase 3. Therefore, retinas were
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Fig. 3 EDN1-induced RGC death was JUN-dependent. a Caspase 3
activation (cleavage, cCASP3, red) in RBPMS+ RGCs (green) 5 days
post-EDN1 in WT, Ddit3−/−, and Jun−/− RGCs. Caspase 3 activation was
not signiﬁcantly lessened in Ddit3−/− RGCs compared to WT
(P > 0.999), and Jun deletion from RGCs with Six3-cre signiﬁcantly
attenuated caspase 3 activation in RGCs compared to WT (*P < 0.001)
and Ddit3−/− retinas (*P = 0.004). cCASP3+ RGCs/mm2 ± SEM for WT,
Ddit3−/−, Jun−/−, respectively: 26.6 ± 8.6; 20.1 ± 4.2; 2.8 ± 0.6; n ≥ 7 per
genotype, *P < 0.001, Kruskal–Wallis test, Dunn’s post hoc. Note:
bottom row images depict RBPMS immunoﬂuorescence (left image,
green) and RBPMS/cCASP3 merged immunoﬂuorescence (right image,
green and red respectively) from the boxed area of the above image.
Arrowheads indicate an RBPMS+ cCASP3+ cell. b %RBPMS+ (green)
RGC survival in WT, Ddit3−/−, Jun−/−, and Ddit3−/−Jun−/− retinas
28 days post-PBS or EDN1. Both WT and Ddit3−/− retinas had
signiﬁcant RGC loss 28 days post-EDN1 insult compared to
corresponding PBS-injected controls, while Jun−/− and Ddit3−/−Jun−/−
retinas did not have signiﬁcant RGC loss (WT: *P < 0.001; Ddit3−/−:
*P = 0.012; Jun−/−: P = 0.139; Ddit3−/−Jun−/−: P = 0.244). Jun−/−
retinas had signiﬁcantly more surviving RGCs after EDN1 compared to
WT (*P = 0.015). Ddit3−/−Jun−/− RGCs were also signiﬁcantly protected
from EDN insult compared to WT (*P = 0.022), but Ddit3−/−Jun−/−
RGCs did not have signiﬁcantly more protection than did Jun−/− RGCs
(P > 0.999). %RGC survival ± SEM for WT, Ddit3−/−, Jun−/−, Ddit3−/−
Jun−/−, respectively: PBS: 100.0 ± 2.4, 100.0 ± 1.9, 100.0 ± 2.2, 100.0 ±
2.0; EDN1: 77.5 ± 2.7, 86.5 ± 3.2, 90.6 ± 3.5, 90.9 ± 3.3; n ≥ 12 per
genotype per condition. Data were analyzed using a two-way ANOVA
with Holm-Sidak’s post hoc test. Note: in some EDN1-injured retinas,
caspase 3 activation in RGCs and RGC loss were localized to portions of
retina and was not necessarily diffuse throughout the entire retina.
Images represent the average cell count for each condition. Error bars,
SEM. Scale bars, 50 μm.

EDN1 caused JUN activation in RGCs

immunoassayed for activated caspase 3 (cleaved caspase 3;
cCASP3) at 3, 5, 10, and 14 days post-EDN1 and PBS
injection. Retinas were counterstained for RBPMS, an
RGC-speciﬁc marker59, to ensure caspase 3 activation was
speciﬁc to RGCs. Intravitreal EDN1 caused caspase 3
activation in RBPMS+ RGCs; this activation peaked 5 days
post injection and was sparse by 14 days post injection.
cCASP3+ RGCs were rarely present at any timepoint postPBS injection (Fig. 1a). Based on the time course of caspase
3 activation in RGCs, the extent of RGC death was assessed
28 days post-EDN1. At this timepoint, there was a 26%
decrease in RBPMS+ RGCs compared to PBS controls
(Fig. 1b). Thus, intravitreal EDN1 was sufﬁcient to cause a
signiﬁcant loss of RGCs by 28 days after insult.
Ofﬁcial journal of the Cell Death Differentiation Association

The apoptotic mechanisms responsible for eliciting RGC
death remain incompletely deﬁned. JUN was shown to
be important in RGC death after glaucoma-relevant
insult22,25,26, and EDN exposure caused JUN upregulation
in cultured primary RGCs33. To determine whether JUN
plays a role in RGC death after EDN insult in vivo, retinas
were immunoassayed for accumulated and activated
(phosphorylated) JUN and RBPMS 1 day following PBS or
EDN1 injection (prior to the onset of caspase 3 activation in
RGCs, Fig. 1a). JUN accumulated and was activated (phosphorylated, pJUN) in 30% of RGCs 1 day following EDN1
injection (Fig. 2a–c), similar to the percentage of RGC death
28 days post-EDN injury (Fig. 1b). Of all pJUN+ cells, the
vast majority (91.4%) were RBPMS+ RGCs, and a small
population labeled an unknown cell type (Fig. 2b). JUN
remained accumulated in RGCs 5 days post-EDN1 insult
(Fig. 2d–f). To determine whether JUN+ RGCs were
eventually the population of RGCs that apoptosed, retinas
were immunoassayed for both JUN and cCASP3 5 days
post-EDN1 insult. Of all cCASP3+ RGCs, 69% were also
JUN positive (Fig. 2e). As a control, cCASP3+ RBPMS+
JUN+ cells were quantiﬁed after controlled optic nerve
crush (CONC); an injury shown to cause RGC death via
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JUN signaling26. Similarly, only a portion (44%) of cCASP3+
RBPMS+ cells were also JUN+ (Fig. 2f). Given JUN accumulates in 100% of RGCs 1 day after CONC26, and only a
portion of cCASP3+ RGCs are also JUN+ 5 days after
CONC, it is likely that at this timepoint, cCASP3+ cells are
in the process of degenerating, and proteins such as JUN are
downregulated. Thus, JUN could feasibly contribute to
EDN1-induced RGC death.
EDN1-induced RGC death was largely JUN-dependent

The cell death pathways governing RGC death after
EDN insult are not well deﬁned. Considering EDN insult
caused activation of JUN in 30% of RGCs (Fig. 2a–c) and
69% of cCASP3+ RGCs were also JUN+ after EDN1 insult
(Fig. 2d–f), it remained possible that JUN regulates EDN1induced RGC death, similar to glaucoma-relevant RGC
death. To determine whether EDN1-induced RGC death
occurs via a JUN-dependent mechanism, Six3-cre+Junﬂ/ﬂ
(herein referred to as Jun−/−) and WT (Six3-cre+Jun+/+;
Six3-cre−Jun?) controls were intravitreally injected with
EDN1 or PBS, and retinas were assessed for apoptotic
RGCs and subsequent RGC loss. Jun deletion signiﬁcantly
lessened caspase 3 activation in RGCs 5 days post insult
(Fig. 3a). Furthermore, retinal Jun deletion signiﬁcantly
attenuated RGC loss by 58% 28 days post insult (Fig. 3b).
Notably, Jun deletion did not protect all RGCs from
EDN1-induced RGC death. This could be due in part to
incomplete recombination of Junﬂ alleles by Six3-cre.
Six3-cre recombined Junﬂ alleles in 80% of RGCs26. Given
Jun deletion by Six3-cre protected fewer than 80% of
RGCs after EDN1 insult, it is likely that another apoptotic
mechanism(s) is important in mediating EDN1-induced
RGC death. DDIT3 (also known as CHOP), a proapoptotic transcription factor activated after prolonged
endoplasmic reticulum stress, moderately contributed to
RGC death after glaucoma-relevant insults26,29,30,60.
Importantly, previous studies have demonstrated that
JUN and DDIT3 additively contributed to RGC death
after axonal injury (Ddit3 and Jun dual deletion prevented 75% of RGC death after RGC axonal insult)26.
Therefore, we tested the effect of Ddit3 deletion alone
and in combination with Jun deletion on RGC survival
after EDN insult. To accomplish this, mice with a
homozygous germline deletion of Ddit3 (Ddit3−/−) and
WT littermate controls were utilized. Ddit3 deletion did
not signiﬁcantly reduce caspase 3 activation 5 days postEDN1 compared to WT controls, and Ddit3 deletion did
not signiﬁcantly prevent RGC death 28 days post-EDN
insult. To determine whether DDIT3 and JUN act in
tandem to drive RGC death after EDN insult, Ddit3−/−
Jun−/− eyes were intravitreally injected with EDN1 or
PBS. Dual deletion of Ddit3 and Jun was signiﬁcantly
protective to RGCs 28 days post injection, but this was
not signiﬁcantly different than the effect of Jun deletion
Ofﬁcial journal of the Cell Death Differentiation Association
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alone. Therefore, EDN1-induced RGC loss was largely
JUN-dependent.
EDN1 induced vasoconstriction and RGC hypoxia

The mechanisms by which EDN1 induces JUN signaling and ultimately apoptosis remains unclear. The
canonical role of the EDN system is to mediate vasoconstriction. EDN ligands are the most potent vasoactive
peptides, and EDN has been shown to cause vasoconstriction through EDNRA expressed by vascular smooth
muscle cells4,7,8,43,44. Importantly, JUN-JNK signaling has
been shown to mediate neuronal death after ischemic
insult47–51. Therefore, it is possible that EDN1 elicits a
hypoxic insult to the retina, which can ultimately lead to
RGC death via JNK-JUN signaling. To determine whether EDN1 elicited retinal vasoconstriction, ﬂuorescein
angiography was utilized at several timepoints postintravitreal injection of either EDN1 or PBS. As previously reported in rats61–63 and rabbits64,65, intravitreal
EDN1 caused rapid retinal vasoconstriction, which lasted
at least 3 h post injection. Retinal vessels appeared normally reperfused after 6 h. No vascular changes occurred
at any timepoint post-PBS (Fig. 4a). Retinal vessel constriction was conﬁrmed ex vivo 5 min post injection.
EDN1 caused signiﬁcant reduction of arterial diameter
(Fig. 4b–d). EDN1 did not change retinal venous diameter. This is not surprising, as EDN ligands cause
vasoconstriction by binding to EDNRA expressed by
vascular smooth muscle cells, which are abundant in
arterial walls but not in veins and therefore elicit more
potent vasoconstriction of arteries66,67. Because vasoconstriction restricts blood ﬂow, pimonidazole HCl
(Hypoxyprobe) was utilized to determine whether
intravitreal EDN1 caused retinal hypoxia. Pimonidazole
forms covalent adducts in cells with a partial pressure of
oxygen <10 mmHg. EDN1-injured retinas had hypoxic
RBPMS+ RGCs and Müller glia somas (labeled by SOX2)
and processes beginning 3 h post injection (data not
shown) and lasting at least out to 24 h (Fig. 4e, f), suggesting that EDN1-induced vasoconstriction caused a
hypoxic insult in the retina.
EDN1 did not cause loss of amacrine cells or Müller glia

Chronic hypoxia has been shown to cause loss of retinal
neurons; including RGCs and amacrine cells68–71. However, in glaucoma, neurodegeneration is speciﬁc to RGCs
and does not affect other retinal neurons, such as amacrine cells72. Therefore, it was important to characterize
whether EDN1 insult affects RGCs speciﬁcally, or whether
EDN1 injures amacrine cells as well, potentially via a
global retinal hypoxic insult. Therefore, choline acetyltransferase (ChAT) immunostaining was utilized to assess
loss of amacrine cells and disruption of synaptic strata in
the inner plexiform layer after EDN1 insult. After 28 days,
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Fig. 4 EDN1 induced vasoconstriction and RGC hypoxia. a Fluorescein angiography of retinal vessels after intravitreal PBS and EDN1 injections.
EDN1 caused potent retinal vasoconstriction beginning rapidly after injection and lasting up to 3 h (arrowheads indicate areas of vasoconstriction at
3 h post-EDN1). Vessels appeared normally perfused by 6 h post injection (n ≥ 3 per condition per timepoint). b Stitched images of retinal ﬂat mounts
immunoassayed with CD31 5 min post-PBS and EDN1 injection. Scale bar, 500 μm. c Higher magniﬁcation of retinal ﬂat mounts immunoassayed with
CD31 5 min post-PBS and EDN1 injection. Veins are indicated with blue “V”s, arteries are indicated with red “A”s. After EDN1 injection, retinal arteries
were markedly thinner compared to PBS. Scale bar, 500 μm. d Quantiﬁcation of arterial and venous diameter 5 min after PBS and EDN1 injection.
Retinal arteries, but not veins, were signiﬁcantly thinner in diameter after EDN1 injection. Artery diameter (μm) ± SEM; PBS: 23.0 ± 1.2; EDN1: 15.2 ± 0.4,
n = 6 per condition, *P < 0.001, Welch’s t-test. Vein diameter (μm)± SEM; PBS: 27.7 ± 2.4; EDN1: 25.6 ± 1.5, n = 6 per condition, P = 0.338, two-tailed t
test. e Retinal sections depicting hypoxia (assessed with pimonidazole, green), RGCs (RBPMS, red), Müller glia (SOX2, magenta), and DAPI (blue) after
intravitreal PBS and EDN1 (note: the EDN1-injured retina depicted in e is 3 stitched images). Regional hypoxia began as early as 3 h post-EDN1 insult
(0/5 PBS exposed retinas and 5/5 EDN1 exposed retinas had pimonidazole + RGCs, data not shown), and continued out to 24 h post insult (0/5 PBSexposed retinas and 5/5-EDN1 exposed retinas had pimonidazole + RGCs and Müller glia). Note: in EDN1-injured retinas, regions of hypoxia were
often localized to portions of retina and were not necessarily diffuse throughout the entire retina. Pictured is an example of several hypoxic regions in
an EDN1-injured retina. ONL outer nuclear layer; OPL outer plexiform layer; INL inner nuclear layer; IPL inner plexiform layer; GCL ganglion cell layer.
Scale bar, 50 μm. f Individual channels depicting pimonidazole (green), RGCs (RBPMS, red), Müller glia (SOX2, magenta), and DAPI (blue) 24 h after PBS
and EDN1. Arrows indicate pimonidazole + RGCs, arrowheads indicate pimonidazole+ Müller glia. Scale bar, 50 μm.

EDN1 did not cause loss of ChAT+ amacrine cells (in the
inner nuclear layer or the ganglion cell layer) or appear to
disrupt the synaptic layers of the inner plexiform layer
(Fig. 5a–d). Because approximately 59% of neurons in the
ganglion cell layer are displaced amacrine cells73, SOX2+
displaced amacrine cell counts were assessed in the
ganglion cell layer following EDN insult. SOX2 labels
starburst amacrine cells in the ganglion cell layer74, which
is by far the most abundant displaced amacrine cell.
Ofﬁcial journal of the Cell Death Differentiation Association

Therefore, SOX2+ cells in the ganglion cell layer were
used to examine the effect of EDN1 insult on amacrine
cells. There was no signiﬁcant difference in the number of
SOX2+ displaced amacrine cells in the ganglion cell layer
between EDN1 and PBS injected eyes 28 days after
injection (Fig. 5e). Therefore, similar to glaucomatous
neurodegeneration, EDN1 insult affected RGCs and did
not appear to cause amacrine cell loss. In addition, because
hypoxyprobe labeling was observed in SOX2+ Müller glia
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Fig. 5 EDN1 did not cause loss of amacrine cells or Müller glia. a Retinal sections depicting choline acetyltransferase + (ChAT, red) amacrine cells
and synaptic strata in the inner plexiform layer 28 days after PBS and EDN1 injection. Amacrine cell synaptic strata were morphologically indistinct
28 days after PBS and EDN1. b Quantiﬁcation of total ChAT+ cells 28 days after PBS and EDN1. EDN1 injured retinas had similar numbers of ChAT+
amacrine cells compared to controls (ChAT+ cells/mm± SEM; PBS: 213.6 ± 4.0; EDN1: 196.4 ± 9.2, n ≥ 3 per condition, P = 0.117, two-tailed t test).
ChAT+ amacrine cell numbers were similar in both the inner nuclear layer (INL; c INL ChAT+ cells/mm ± SEM; PBS: 115.3 ± 3.3; EDN1: 105.8 ± 11.3,
n ≥ 3 per condition, P = 0.394, two-tailed t test) and the ganglion cell layer (GCL; d, GCL ChAT+ cells/mm± SEM; PBS: 98.3 ± 2.1; EDN1: 90.6 ± 2.2, n ≥ 3
per condition, P = 0.058, two-tailed t test). e Retinal ﬂat mounts depicting SOX2+ amacrine cells in the ganglion cell layer 28 days after PBS and EDN1
injection. EDN1 did not cause signiﬁcant loss of SOX2 + amacrine cells (SOX2 + cell survival ± SEM; PBS: 1263 ± 35.8; EDN1: 1204 ± 58.1; n = 7 per
condition, P = 0.406, two-tailed t test). f Retinal sections depicting SOX2+ (green) Müller glia 28 days post-PBS and EDN1 injection. EDN1 did not
appear to cause loss of SOX2+ Müller glia. Note: SOX2 labels a population of amacrine cells in the inner portion of the INL and in the GCL. Müller glia
were distinguished from amacrine cells by location in the INL and by morphology in accordance with Surzenko et al.81. Arrowheads indicate SOX2+
amacrine cells in the INL that were not included in this quantiﬁcation. (SOX2+ Müller glia/mm ± SEM; PBS: 783.1 ± 19.2; EDN1: 718 ± 22.0; n ≥ 3 per
condition, P = 0.081, two-tailed t test). ONL outer nuclear layer; OPL outer plexiform layer; INL inner nuclear layer; IPL inner plexiform layer; GCL
ganglion cell layer. Error bars, SEM. Scale bars, 50 μm.

after EDN1 insult, it was important to determine whether
EDN1 insult elicited loss of Müller glia in addition to
RGCs. After 28 days, EDN1 did not cause signicant loss of
SOX2+ Müller glia (Fig. 5f). Therefore, EDN1 did not
appear to cause a global retinal hypoxic insult.
Ofﬁcial journal of the Cell Death Differentiation Association

Discussion
Endothelin has been implicated as a mediator of glaucomatous RGC death1,2,4–6,13,14,34,75,76. Components of
EDN signaling were upregulated in human3,18–20 and
animal models of glaucoma1,5,6,14–17, and genetic deletion
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or antagonism of EDN receptors lessened glaucomatous
damage in ocular hypertensive rodents5. Several groups
have demonstrated EDN’s capacity to kill RGCs2,4–6,21.
However, the mechanisms important in driving RGC
death after EDN insult remain unidentiﬁed. Understanding the cell death pathways important in EDNinduced RGC death will further elucidate the earliest
molecular mechanisms of glaucoma pathology and can
potentially identify therapeutic targets for neuroprotection. In the present work, EDN1 insult to RGCs was
characterized in vivo, and the roles of Ddit3 and Jun in
eliciting RGC death after EDN1 insult were assessed.
The cell-intrinsic mechanisms of EDN-induced RGC
death remain incompletely understood. Given the relevance of EDN signaling to glaucomatous neurodegeneration, it is possible that EDN elicits RGC death via cell
death pathways known to govern RGC death after
glaucoma-relevant insult. MAPK-JNK signaling and its
canonical target JUN regulated RGC death after
glaucoma-relevant insults such as axonal injury22,26 and
chronic ocular hypertension25. Similarly, but to a lesser
extent, the endoplasmic reticulum stress effector and
transcription factor DDIT3 played a role in RGC death
after axonal injury26 and ocular hypertension30. Dual
deletion of Jun and Ddit3 conferred near-complete protection to RGCs after axonal insult26. MAPKs-including
JNK- and JUN have been shown to act downstream of
EDN receptors in multiple cell types31,77,78, including
RGCs33. In addition, EDN receptors have been shown to
potentiate the endoplasmic reticulum stress response, and
Ddit3 has been shown to act downstream of EDN
receptors. Therefore, it remained possible that JUN and/
or DDIT3 mediate RGC death in response to EDN.
In the present study, JUN was activated in 30% of RGCs
1 day post-EDN1 (Fig. 2a–c), and Jun deletion signiﬁcantly attenuated RGC caspase 3 activation and RGC
loss (Fig. 3a, b). This protection (58% increased RGC
survival) is approximately commensurate to levels of
protection conferred by Jun deletion in models of axonal
injury (48% protection 120 days post injury)26 and chronic
ocular hypertension (47% protection)25. In contrast, we
found Ddit3 deletion did not provide signiﬁcant protection from EDN-induced RGC death. These data do not
preclude the possibility that Ddit3 deletion protected a
small portion of RGCs after EDN insult that was not
detected with our experimental design. This possibility is
not unlikely, as Ddit3 deletion protected only 25% of
RGCs 120 days post-axonal insult26 and 20% of RGCs in
ocular hypertensive mice30. Nevertheless, these data suggest that DDIT3 did not govern the majority of RGC
death following EDN insult. Future work should elucidate
the upstream regulators of JUN activation and the
downstream targets of JUN signaling to further clarify the
molecular mechanisms governing RGC apoptosis in
Ofﬁcial journal of the Cell Death Differentiation Association
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response to EDN signaling. For instance, MAP3K12
(DLK)23,26, MAP2Ks 4 and 7 (MKK4, MKK7)79, and
MAPKs 9 and 10 (JNK2, JNK3)22 are upstream regulators
of JUN activation and were shown to be important in
mediating glaucoma-relevant RGC death, and are perhaps
important in regulating EDN-induced RGC death.
Furthermore, it will be important to determine whether
Jun deletion protects RGC axons as well as somas after
EDN insult. JUN has been shown to regulate RGC somal
degeneration, but not axonal degeneration, after RGC
axonal injury and chronic ocular hypertension. Theoretically, if EDN1 injures RGCs at the level of the soma, Jun
deletion would likely confer protection to RGC axons as
well as somas. However, if EDN1 causes a primary injury
to RGC axons, Jun deletion could potentially confer
protection to RGC somas, but not axons. Further dissecting the role of Jun in the degeneration of RGC somas
and axons will be important for understanding EDN1induced RGC death, and can possibly classify the location
of EDN1 insult to RGCs (somal or axonal).
In addition to the cell death pathways important in eliciting RGC death after EDN insult, the retinal cell types
that respond to EDN ligand and ultimately cause RGC
death remain unknown. A multitude of cell types express
EDN receptors; retinal neurons (including RGCs) and
macroglia are known to express EDNRB, while RGCs and
retinal mural cells are known to express EDNRA. While it
is possible that EDN ligands affect RGCs directly (via
receptors expressed by RGCs), it is also possible that EDN
ligands signal extrinsically to RGCs by affecting glia or
vascular cells and eliciting neurotoxic downstream effects;
ultimately causing JUN-mediated RGC death. Regardless of
the primary cell type EDN1 acts upon to ultimately cause
RGC death, the present study indicates that ultimately, JUN
is important in RGC degeneration after EDN1 exposure.
The canonical role of EDN signaling is to mediate
vasoconstriction4,7,8,43. EDN ligands bind to EDNRA
expressed by vascular mural cells, which elicits contraction of vascular smooth muscle cells and consequential
vasoconstriction4,7,8,43,44. Thinner retinal vessels and
reduced blood ﬂow have been reported in human9–12,80
and animal models of glaucoma5,6. Notably, JNK-JUN
signaling was found to contribute to neuronal death after
ischemic insult to the rodent brain47–50 and retina51.
Therefore, it is possible that aberrant EDN signaling via
mural cell-EDNRA contributes to reduced retinal blood
ﬂow in glaucoma, which could in turn perpetuate neurodegeneration via JNK-JUN signaling.
Consistent with previous reports using rats61–63 and
rabbits64,65, we found intravitreal EDN1 caused potent but
transient arterial constriction in the mouse retina, which
reperfused by 6 h post injection (Fig. 4a–d). Subsequently,
EDN1 insult resulted in regions of hypoxic RGCs and
Müller glia beginning 3 h (data not shown) and lasting at
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least 24 h post injection (Fig. 4b, c). Hypoxic glia and
RGCs were also reported after induction of ocular
hypertension, suggesting the potential importance of
hypoxia in glaucoma pathology45,46. RGC death did not
necessarily occur in close proximity to major vessels after
EDN1 insult, but it is possible that loss of blood ﬂow or
damage to minor vessels and capillary beds contributes to
EDN pathology. Future studies should investigate the
effect of EDN on retinal vessel integrity, and how any
changes may play a role in EDN-induced RGC death.
Severe hypoxia is known to cause RGC and amacrine cell
loss, however, we observed RGC loss (Fig. 1b) but not loss
of ChAT+ or SOX2+ amacrine cells after EDN1 insult
(Fig. 5a–e); consistent with glaucomatous neurodegeneration. In addition, although Müller glia hypoxia was
observed 24 h after EDN1 insult, Müller glia survival
appeared unaffected 28 days after EDN1. Thus, in the
present study, EDN1-induced cell death appeared to be
speciﬁc to RGCs, similar to glaucoma pathology, and it
remains possible that hypoxia plays a role in glaucomatous and EDN-induced RGC death. Future work should
elucidate the role of EDNRA and hypoxia in mediating
RGC death after EDN1 insult and in models of glaucoma.
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